Q2 Medicine
Bushra Mustafa Salman, Omar Ayaad, Rawan Ibrahim, Manal Salim AlHatrushi, Mohamad Majed, Razzan Al Zadjali, Zainab Abdullah AlTobi, Abier Atabani, Ghalia Mubarak AlHasani, Malouk Nasser AlMusheifri, Mohamed Ibrahim El Kholy, Sara Al Sheedi, Nabiha Said AlHasni, Amna Khamis Al-Hashar, Huda Shinoon Al-Awaisi, Khalid Al-Baimani
{"title":"Enhancing Medication Safety: Reducing Administration Errors in Oncology Setting.","authors":"Bushra Mustafa Salman, Omar Ayaad, Rawan Ibrahim, Manal Salim AlHatrushi, Mohamad Majed, Razzan Al Zadjali, Zainab Abdullah AlTobi, Abier Atabani, Ghalia Mubarak AlHasani, Malouk Nasser AlMusheifri, Mohamed Ibrahim El Kholy, Sara Al Sheedi, Nabiha Said AlHasni, Amna Khamis Al-Hashar, Huda Shinoon Al-Awaisi, Khalid Al-Baimani","doi":"10.31557/APJCP.2025.26.1.269","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>This project aimed to minimize medication errors and improve safe medication administration in an oncology setting in Muscat, Oman.</p><p><strong>Methods: </strong>The study, spanning from the second quarter of 2022 to the first quarter of 2023, employed a one-group pretest-posttest quasi-experimental design, assessing key performance indicators (medication error and medication administration errors rates per 1000 patient days) on quarterly basis before and after implementing targeted interventions.  Interventions focused on medication management processes and Healthcare Informatics System (HIS), Environment and equipment, and Education The project utilized the FOCUS PDCA (find, organize, clarify, understand, select, plan, do, check and act) methodology. Ethical clearance was obtained from the Institutional Review Board.</p><p><strong>Results: </strong>The results showed significant reductions were observed in both medication error and medication administration error rates following the implementation of interventions. Specifically, the medication error rate decreased from 12.59 in the Second Quarter of 2022 (pre-intervention) to 5.26 in the Fourth Quarter of 2023 (post-intervention), with an overall ANOVA F-value of 9.2950 (p = 0.035). Similarly, the medication administration error rate declined from 5.39 to 1.29 over the same period, resulting in an ANOVA F-value of 8.2320 (p = 0.044).</p><p><strong>Conclusion: </strong>The study indicates a significant improvement in patient safety outcomes following the intervention implementation, underscoring the effectiveness of the interventions in reducing medication errors and administration errors.</p>","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"26 1","pages":"269-277"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Pacific Journal of Cancer Prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31557/APJCP.2025.26.1.269","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

目的:该项目旨在最大限度地减少用药错误,提高阿曼马斯喀特肿瘤医院的安全用药水平:研究时间跨度为 2022 年第二季度至 2023 年第一季度,采用单组前测后测准实验设计,在实施有针对性的干预措施前后,每季度评估一次关键绩效指标(每 1000 个患者日的用药错误率和用药管理错误率)。 该项目采用了 FOCUS PDCA(查找、组织、澄清、理解、选择、计划、执行、检查和行动)方法。项目获得了机构审查委员会的伦理许可:结果表明,在实施干预措施后,用药错误率和用药错误率都有明显下降。具体而言,用药错误率从 2022 年第二季度(干预前)的 12.59 降至 2023 年第四季度(干预后)的 5.26,总体方差分析 F 值为 9.2950(p = 0.035)。同样,同期的用药错误率从 5.39 降至 1.29,方差分析 F 值为 8.2320(p = 0.044):研究表明,实施干预措施后,患者安全状况得到了明显改善,这突出表明了干预措施在减少用药错误和管理错误方面的有效性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Enhancing Medication Safety: Reducing Administration Errors in Oncology Setting.

Purpose: This project aimed to minimize medication errors and improve safe medication administration in an oncology setting in Muscat, Oman.

Methods: The study, spanning from the second quarter of 2022 to the first quarter of 2023, employed a one-group pretest-posttest quasi-experimental design, assessing key performance indicators (medication error and medication administration errors rates per 1000 patient days) on quarterly basis before and after implementing targeted interventions.  Interventions focused on medication management processes and Healthcare Informatics System (HIS), Environment and equipment, and Education The project utilized the FOCUS PDCA (find, organize, clarify, understand, select, plan, do, check and act) methodology. Ethical clearance was obtained from the Institutional Review Board.

Results: The results showed significant reductions were observed in both medication error and medication administration error rates following the implementation of interventions. Specifically, the medication error rate decreased from 12.59 in the Second Quarter of 2022 (pre-intervention) to 5.26 in the Fourth Quarter of 2023 (post-intervention), with an overall ANOVA F-value of 9.2950 (p = 0.035). Similarly, the medication administration error rate declined from 5.39 to 1.29 over the same period, resulting in an ANOVA F-value of 8.2320 (p = 0.044).

Conclusion: The study indicates a significant improvement in patient safety outcomes following the intervention implementation, underscoring the effectiveness of the interventions in reducing medication errors and administration errors.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
2.80
自引率
0.00%
发文量
779
审稿时长
3 months
期刊介绍: Cancer is a very complex disease. While many aspects of carcinoge-nesis and oncogenesis are known, cancer control and prevention at the community level is however still in its infancy. Much more work needs to be done and many more steps need to be taken before effective strategies are developed. The multidisciplinary approaches and efforts to understand and control cancer in an effective and efficient manner, require highly trained scientists in all branches of the cancer sciences, from cellular and molecular aspects to patient care and palliation. The Asia Pacific Organization for Cancer Prevention (APOCP) and its official publication, the Asia Pacific Journal of Cancer Prevention (APJCP), have served the community of cancer scientists very well and intends to continue to serve in this capacity to the best of its abilities. One of the objectives of the APOCP is to provide all relevant and current scientific information on the whole spectrum of cancer sciences. They aim to do this by providing a forum for communication and propagation of original and innovative research findings that have relevance to understanding the etiology, progression, treatment, and survival of patients, through their journal. The APJCP with its distinguished, diverse, and Asia-wide team of editors, reviewers, and readers, ensure the highest standards of research communication within the cancer sciences community across Asia as well as globally. The APJCP publishes original research results under the following categories: -Epidemiology, detection and screening. -Cellular research and bio-markers. -Identification of bio-targets and agents with novel mechanisms of action. -Optimal clinical use of existing anti-cancer agents, including combination therapies. -Radiation and surgery. -Palliative care. -Patient adherence, quality of life, satisfaction. -Health economic evaluations.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信